Novo Nordisk A/S Study: Degludec Cuts Night-Time Hypoglycemia Risk

Published: Oct 03, 2012

A new study shows that insulin degludec, an investigational diabetes drug developed by the world's largest insulin maker, Novo Nordisk A/S (NOVO-B.KO), sharply cuts diabetes patients' risk of incurring night-time hypoglycaemia compared with traditional insulin, the company said Tuesday. Compared with insulin glargine, patients had a 43% lower rate of night-time hypoglycaemia, according to the two-year study, which investigated 1,030 patients with type 2 diabetes. The patients, who hadn't previously been treated with insulin, also had a significantly lower rate of severe hypoglycaemia, according to the data, which were presented at the Annual Meeting of the European Association for the Study of Diabetes in Berlin.

Back to news